The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings.

Liquidia Corporation, a biopharmaceutical company developing innovative therapies for patients with rare cardiopulmonary diseases, and Pharmosa Biopharm (Pharmosa) announced that they have amended the ...

Liquidia Corporation LQDA has entered into an exclusive licensing agreement with Pharmosa Biopharm for the development and commercialization of L606 in North America. L606 is an inhaled, twice-daily ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions.

Pharmosa to receive $3.5 million upfront and up to $157.75 million in additional development and sales milestones tied to commercial sales outside of North America MORRISVILLE, N.C., Oct. 02, 2024 ...

Liquidia amends exclusive license to include key markets in Europe, Japan and elsewhere Liquidia also obtains rights to Pharmosa's next-generation nebulizers for use with L606 Pharmosa to receive $3.5 ...

Pharmosa will continue to manufacture clinical and commercial supplies of L606. In consideration for these incremental exclusive rights, Liquidia will pay Pharmosa an upfront payment of $3.5 million ...